AAPGNasdaqPharmaceutical PreparationsFiscal year ends December 31
ASCENTAGE PHARMA GROUP INTERNATIONAL
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026
$15.36−0.01 (-0.07%)
Close on Oct 19, 2026
ASCENTAGE PHARMA GROUP INTERNATIONAL revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Types of goods or services [Member] | CN¥574.12M | CN¥980.65M | CN¥221.98M | CN¥209.71M | 100.0% | -41.5% |
| Products | CN¥499.27M | CN¥260.84M | CN¥193.54M | CN¥174.93M | 87.0% | +91.4% |
| Others | CN¥74.85M | CN¥41.40M | CN¥28.45M | CN¥34.78M | 13.0% | +80.8% |
| Intellectual Property | – | CN¥678.42M | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Chinese Mainland [Member] | CN¥574.12M | CN¥302.24M | CN¥221.98M | CN¥209.71M | 100.0% | +90.0% |
| United States | – | – | – | CN¥4.00K | – | – |
| Switzerland | – | CN¥678.42M | – | – | – | – |
From the segment and revenue-disaggregation notes of Ascentage Pharma Group International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.